CYP2C9 Gene (Protein Coding)

Cytochrome P450 Family 2 Subfamily C Member 9

GC10P094938
GIFtS:
50
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobioti... See more...

Aliases for CYP2C9 Gene

Aliases for CYP2C9 Gene

  • Cytochrome P450 Family 2 Subfamily C Member 9 2 3 5
  • Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 2 3
  • Cytochrome P450 PB-1 3 4
  • Cytochrome P450 2C9 3 4
  • Cytochrome P-450MP 3 4
  • EC 1.14.14.1 4 52
  • CYP2C10 3 4
  • CYPIIC9 3 4
  • Cytochrome P450, Subfamily IIC (Mephenytoin 4-Hydroxylase), Polypeptide 9 2
  • Cytochrome P-450 S-Mephenytoin 4-Hydroxylase 3
  • Flavoprotein-Linked Monooxygenase 3
  • (R)-Limonene 6-Monooxygenase 4
  • (S)-Limonene 6-Monooxygenase 4
  • (S)-Limonene 7-Monooxygenase 4
  • S-Mephenytoin 4-Hydroxylase 4
  • Cholesterol 25-Hydroxylase 4
  • Microsomal Monooxygenase 3
  • Xenobiotic Monooxygenase 3
  • Cytochrome P450 MP-4 4
  • Cytochrome P450 MP-8 4
  • EC 1.14.14.53 4
  • EC 1.14.14.51 4
  • EC 1.14.14.52 4
  • P450IIC9 3
  • CYP2C 3
  • CPC9 3

External Ids for CYP2C9 Gene

Previous HGNC Symbols for CYP2C9 Gene

  • CYP2C10

Previous GeneCards Identifiers for CYP2C9 Gene

  • GC10P095591
  • GC10P095932
  • GC10P096829
  • GC10P096363
  • GC10P096688
  • GC10P090325

Summaries for CYP2C9 Gene

Entrez Gene Summary for CYP2C9 Gene

  • This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]

GeneCards Summary for CYP2C9 Gene

CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) is a Protein Coding gene. Diseases associated with CYP2C9 include Coumarin Resistance and Vitamin K Antagonists Toxicity Or Dose Selection. Among its related pathways are Drug metabolism - cytochrome P450 and Naphthalene metabolism. Gene Ontology (GO) annotations related to this gene include oxidoreductase activity and heme binding. An important paralog of this gene is CYP2C19.

UniProtKB/Swiss-Prot Summary for CYP2C9 Gene

  • A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031).

Gene Wiki entry for CYP2C9 Gene

PharmGKB "VIP" Summary for CYP2C9 Gene

Additional gene information for CYP2C9 Gene

No data available for CIViC Summary , Tocris Summary , Rfam classification and piRNA Summary for CYP2C9 Gene

Genomics for CYP2C9 Gene

GeneHancer (GH) Regulatory Elements for CYP2C9 Gene

Promoters and enhancers for CYP2C9 Gene
GeneHancer (GH) Identifier GH Type GH
Score		 GH Sources Gene Association Score Total Score TSS distance (kb) Number of Genes Away Size (kb) Transcription Factor
Binding Sites		 Gene Targets
GH10J094901 Promoter/Enhancer 1.2 EPDnew ENCODE 500.3 -35.0 -34969 4.7 TCF12 NCOR1 KDM6A KLF4 ZBTB25 SKI TEAD1 TBX3 ZSCAN9 FOXA2 CYP2C9 ACSM6 CYP2C19 CYP2C115P piR-47086-042
GH10J094938 Promoter 0.7 EPDnew 500.7 0.0 -19 0.1 JUND RXRA MAX HNF4A REST FOXA1 YY1 TAF1 RAD21 HNF4G CYP2C9 piR-48222-053
GH10J094679 Promoter/Enhancer 1.5 EPDnew Ensembl ENCODE 4.7 -256.2 -256227 5.9 TCF12 NCOR1 TEAD1 ZKSCAN8 FOXA2 NR2F2 CREB1 CEBPB SAP130 FOSL2 CYP2C18 ACSM6 CYP2C19 MTND4P19 NOC3L CYP2C9 piR-33605-061
GH10J095220 Enhancer 0.9 Ensembl ENCODE dbSUPER 4.6 +282.8 282805 2.5 TCF12 TEAD4 TEAD1 FOXA2 FOSL2 FOXA1 HOMEZ RARA TEAD3 JUND lnc-PDLIM1-3 ACSM6 PDLIM1 CYP2C8 CYP2C9 ENSG00000234026
GH10J094212 Enhancer 0.8 Ensembl ENCODE 3.9 -724.8 -724796 2.7 FOXA2 POLR2A NR2F2 CEBPB ZBTB33 JUND FOSL2 RAD21 USF2 RXRA NOC3L MTND4P19 HELLS CYP2C9 ENSG00000228553 piR-58308-044 PLCE1
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around CYP2C9 on UCSC Golden Path with GeneCards custom track

Cistromic (ChIP-Seq) regulation report from SPP (The Signaling Pathways Project) for CYP2C9

Top Transcription factor binding sites by QIAGEN in the CYP2C9 gene promoter:
  • COUP
  • COUP-TF
  • COUP-TF1
  • GATA-1
  • HNF-4alpha1
  • HNF-4alpha2
  • HOXA5
  • PPAR-gamma1
  • PPAR-gamma2

Genomic Locations for CYP2C9 Gene

Genomic Locations for CYP2C9 Gene
chr10:94,938,658-94,990,091
(GRCh38/hg38)
Size:
51,434 bases
Orientation:
Plus strand
chr10:96,698,415-96,749,148
(GRCh37/hg19)
Size:
50,734 bases
Orientation:
Plus strand

Genomic View for CYP2C9 Gene

Genes around CYP2C9 on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
CYP2C9 Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for CYP2C9 Gene
GeneLoc Logo Genomic Neighborhood • Exon Structure • Gene Density

RefSeq DNA sequence for CYP2C9 Gene

Proteins for CYP2C9 Gene

Products:

  1. Antibody
  2. Protein
  3. Assay

  • Protein details for CYP2C9 Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    P11712-CP2C9_HUMAN
    Recommended name:
    Cytochrome P450 2C9
    Protein Accession:
    P11712
    Secondary Accessions:
    • P11713
    • Q16756
    • Q16872
    • Q5VX92
    • Q6IRV8
    • Q8WW80

    Protein attributes for CYP2C9 Gene

    Size:
    490 amino acids
    Molecular mass:
    55628 Da
    Cofactor:
    Name=heme; Xref=ChEBI:CHEBI:30413;
    Quaternary structure:
    No Data Available

    Three dimensional structures from OCA and Proteopedia for CYP2C9 Gene

    Alternative splice isoforms for CYP2C9 Gene

    UniProtKB/Swiss-Prot:

neXtProt entry for CYP2C9 Gene

Protein Expression for CYP2C9 Gene

See protein expression from ProteomicsDB, MOPED, PaxDb, and MaxQB

Selected DME Specific Peptides for CYP2C9 Gene

P11712:
  • CLVEELRK
  • LTSVLHD
  • FGMGKRS
  • YGPVFTLY
  • EEFSGRG
  • EKVKEHQ
  • GMGKRSIE
  • PFSAGKR
  • PGPTPLP
  • GKRICVGE
  • LLLLLKHP
  • IEDRVQEEA
  • LPHAVTCD
  • RRFSLMTL
  • KEFPNPE
  • GYEAVKEAL
  • CDPTFIL
  • EEIERVIG
  • GKLPPGP
  • VVLVLCLS
  • TTSTTLRY
  • DIKFRNY
  • AGTETTS
  • KFRNYLIPKGT
  • TAKVQEEI
  • PCNVICS

Post-translational modifications for CYP2C9 Gene

  • Modification sites at PhosphoSitePlus
  • Modification sites at neXtProt

Other Protein References for CYP2C9 Gene

ENSEMBL proteins:
REFSEQ proteins:

Domains & Families for CYP2C9 Gene

Gene Families for CYP2C9 Gene

HGNC:
IUPHAR :
Human Protein Atlas (HPA):
  • Enzymes
  • Predicted intracellular proteins

Protein Domains for CYP2C9 Gene

Blocks:
  • E-class P450 group I signature
  • CYP2B P450 family signature
InterPro:
ProtoNet:

Suggested Antigen Peptide Sequences for CYP2C9 Gene

GenScript: Design optimal peptide antigens:
  • S-mephenytoin 4-hydroxylase (CP2C9_HUMAN)
  • Cytochrome p4502C9 (Q5EDC5_HUMAN)
  • cDNA FLJ75561, highly similar to Homo sapiens cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9), mRNA (Q5VX92_HUMAN)
  • CYP2C9 protein (Q6IRV8_HUMAN)
  • Cytochrome P450, family 2, subfamily C, polypeptide 9, isoform CRA_a (Q8WW80_HUMAN)

Graphical View of Domain Structure for InterPro Entry

P11712

UniProtKB/Swiss-Prot:

CP2C9_HUMAN :
  • Belongs to the cytochrome P450 family.
Family:
  • Belongs to the cytochrome P450 family.
genes like me logo Genes that share domains with CYP2C9: view

Function for CYP2C9 Gene

Products:

  1. Animal Model
  2. CRISPR
  3. miRNA
  4. Inhibitory RNA
  5. Clone
  6. Cell Line

Molecular function for CYP2C9 Gene

UniProtKB/Swiss-Prot Function:
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031).
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=an organic molecule + O2 + reduced [NADPH--hemoprotein reductase] = an alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17149, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30879, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:142491; EC=1.14.14.1; Evidence={ECO:0000269 PubMed:12865317, ECO:0000269 PubMed:21576599, ECO:0000269 PubMed:9435160, ECO:0000269 PubMed:9866708}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17150; Evidence={ECO:0000305 PubMed:12865317, ECO:0000305 PubMed:21576599, ECO:0000305 PubMed:9435160, ECO:0000305 PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (8R,9S)-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49884, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131975; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:49885; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (8S,9R)-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49928, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131974; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:49929; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (11R,12S)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49880, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131970; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:49881; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (11S,12R)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49876, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131969; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:49877; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49860, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131965; Evidence={ECO:0000269 PubMed:19965576, ECO:0000269 PubMed:7574697}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:49861; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49856, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131964; Evidence={ECO:0000269 PubMed:19965576, ECO:0000269 PubMed:7574697}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:49857; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 8,9-epoxy-(5Z,11Z,14Z,17Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52168, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:136439; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52169; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 11,12-epoxy-(5Z,8Z,14Z,17Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52172, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:136441; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52173; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 14,15-epoxy-(5Z,8Z,11Z,17Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52176, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:136443; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52177; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = (17R,18S)-epoxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39779, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76634; Evidence={ECO:0000269 PubMed:15766564, ECO:0000269 PubMed:19965576}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39780; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 25-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50256, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:42977, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50257; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxy-17beta-estradiol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47212, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:28744, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47213; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=estrone + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxyestrone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47208, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:1156, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17263, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47209; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (11R)-hydroxy-(5Z,8Z,12E,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52492, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78836; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52493; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (12R)-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52300, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:83343; Evidence={ECO:0000269 PubMed:9435160, ECO:0000269 PubMed:9866708}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52301; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (15R)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52496, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78837; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52497; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 10-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52296, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:133345; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52297; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9Z,12Z)-octadecadienoate + O2 + reduced [NADPH--hemoprotein reductase] = (13R)-hydroxy-(9Z,11E)-octadecadienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52500, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30245, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136655; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52501; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9Z,12Z)-octadecadienoate + O2 + reduced [NADPH--hemoprotein reductase] = 9(R)-hydroxy-(10E,12Z)-octadecadienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52504, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30245, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77895; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52505; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 19-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39759, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76627; Evidence={ECO:0000269 PubMed:9435160, ECO:0000269 PubMed:9866708}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39760; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 13(S)-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52508, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136654; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52509; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:51472, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84024; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51473; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:51480, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76625; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51481; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 13-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52292, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136524; Evidence=. ; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52293; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4R)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (1R,5S)-carveol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:18957, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15382, ChEBI:CHEBI:15388, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.53; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4S)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (1S,5R)-carveol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17945, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15383, ChEBI:CHEBI:15389, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.51; Evidence=. ;.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4S)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (4S)-perillyl alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:23432, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:10782, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15383, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.52; Evidence=. ;.
UniProtKB/Swiss-Prot BiophysicochemicalProperties:
Kinetic parameters: KM=12.2 uM for (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate (epoxygenation) {ECO:0000269 PubMed:15766564}; KM=14.3 uM for (5Z,8Z,11Z,14Z)-eicosatetraenoate (epoxygenation) {ECO:0000269 PubMed:15766564}; KM=1.25 mM for S-mephenytoin {ECO:0000269 PubMed:3079764}; KM=46.24 uM for tolbutamide {ECO:0000269 PubMed:25994031}; KM=4.73 uM for diclofenac {ECO:0000269 PubMed:25994031}; KM=1.58 uM for losartan {ECO:0000269 PubMed:25994031}; Vmax=210.30 pmol/min/pmol enzyme with losartan as substrate {ECO:0000269 PubMed:25994031}; Vmax=29.1 nmol/min/nmol enzyme toward (5Z,8Z,11Z,14Z,17Z)- eicosapentaenoate (epoxidation) {ECO:0000269 PubMed:15766564}; Vmax=29.2 nmol/min/nmol enzyme toward (5Z,8Z,11Z,14Z)- eicosatetraenoate (epoxidation) {ECO:0000269 PubMed:15766564}; Vmax=9.22 pmol/min/pmol enzyme with tolbutamide as substrate {ECO:0000269 PubMed:25994031}; Vmax=17.16 pmol/min/pmol enzyme with diclofenac as substrate {ECO:0000269 PubMed:25994031};
UniProtKB/Swiss-Prot Induction:
By rifampicin.
GENATLAS Biochemistry:
cytochrome P450,subfamily IIC (mephenytoin 4-hydroxylase),polypeptide 9

Enzyme Numbers (IUBMB) for CYP2C9 Gene

Phenotypes From GWAS Catalog for CYP2C9 Gene

Gene Ontology (GO) - Molecular Function for CYP2C9 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0004497 monooxygenase activity NAS 2827463
GO:0005506 iron ion binding IEA --
GO:0008144 drug binding IDA 19448135
GO:0008392 arachidonic acid epoxygenase activity IDA 7574697
GO:0008395 steroid hydroxylase activity IMP 18356043
genes like me logo Genes that share ontologies with CYP2C9: view
genes like me logo Genes that share phenotypes with CYP2C9: view

Human Phenotype Ontology for CYP2C9 Gene

HPO Id HPO Name Alternative Ids Definition Synonyms

Animal Model Products

CRISPR Products

miRNA for CYP2C9 Gene

miRTarBase miRNAs that target CYP2C9

Clone Products

No data available for Animal Models , Transcription Factor Targets and HOMER Transcription for CYP2C9 Gene

Localization for CYP2C9 Gene

Subcellular locations from UniProtKB/Swiss-Prot for CYP2C9 Gene

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for CYP2C9 gene
Compartment Confidence
endoplasmic reticulum 5
plasma membrane 2
extracellular 2
cytoskeleton 2
mitochondrion 2
peroxisome 2
nucleus 2
cytosol 2
endosome 1
lysosome 1
golgi apparatus 1

Gene Ontology (GO) - Cellular Components for CYP2C9 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0005737 cytoplasm IBA 21873635
GO:0005783 endoplasmic reticulum IEA --
GO:0005789 endoplasmic reticulum membrane TAS --
GO:0016020 membrane IEA --
GO:0031090 organelle membrane IEA --
genes like me logo Genes that share ontologies with CYP2C9: view

No data available for Subcellular locations from the Human Protein Atlas (HPA) for CYP2C9 Gene

Pathways & Interactions for CYP2C9 Gene

PathCards logo

SuperPathways for CYP2C9 Gene

SuperPathway Contained pathways
1 Drug metabolism - cytochrome P450
Drug metabolism - cytochrome P450
.72
Metabolism of xenobiotics by cytochrome P450
.72
Chemical carcinogenesis
.68
Retinol metabolism
.32
Retinol metabolism
.31
Celecoxib Pathway, Pharmacokinetics
.01
Fluoxetine Pathway, Pharmacokinetics
.01
Haloperidol Pathway, Pharmacokinetics
.01
Ifosfamide Pathway, Pharmacokinetics
.01
Naproxen Pathway, Pharmacokinetics
.01
Sertraline Pathway, Pharmacokinetics
.01
Voriconazole Pathway, Pharmacokinetics
.01
Benzo[a]pyrene metabolism
.01
2 Cytochrome P450 - arranged by substrate type
Cytochrome P450 - arranged by substrate type
.64
Oxidation by Cytochrome P450
.64
Phase 1 - Functionalization of compounds
.63
Biological oxidations
.49
Xenobiotics
.39
Metapathway biotransformation
.36
CYP2E1 reactions
.01
Estradiol metabolism
.01
Vitamin D2 (ergocalciferol) metabolism
.01
3 Statin Pathway - Generalized, Pharmacokinetics
Ibuprofen Pathway, Pharmacokinetics
.42
Statin Pathway - Generalized, Pharmacokinetics
.42
Diclofenac Pathway, Pharmacokinetics
.39
Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
.01
Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
.01
Clobazam Pathway, Pharmacokinetics
.01
Fluvastatin Pathway, Pharmacokinetics
.01
Rosiglitazone Pathway, Pharmacokinetics
.01
4 Imipramine/Desipramine Pathway, Pharmacokinetics
Amitriptyline and Nortriptyline Pathway, Pharmacokinetics
.50
Warfarin Pathway, Pharmacokinetics
.40
Clozapine Pathway, Pharmacokinetics
.38
Nevirapine Pathway, Pharmacokinetics
.30
Candesartan Pathway, Pharmacokinetics
.01
Doxepin Pathway, Pharmacokinetics
.01
Metoprolol Pathway, Pharmacokinetics
.01
5 Metabolism
Metabolic pathways
.40
Metabolism
.40
Metabolism of lipids and lipoproteins
.37
genes like me logo Genes that share pathways with CYP2C9: view

UniProtKB/Swiss-Prot P11712-CP2C9_HUMAN

  • Pathway: Lipid metabolism; arachidonate metabolism.
  • Pathway: Steroid metabolism; cholesterol metabolism.
  • Pathway: Terpene metabolism; (4R)-limonene degradation.

Gene Ontology (GO) - Biological Process for CYP2C9 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0006082 organic acid metabolic process IBA 21873635
GO:0006629 lipid metabolic process IEA --
GO:0006805 xenobiotic metabolic process TAS --
GO:0008202 steroid metabolic process IMP 18356043
GO:0008203 cholesterol metabolic process IEA --
genes like me logo Genes that share ontologies with CYP2C9: view

No data available for SIGNOR curated interactions for CYP2C9 Gene

Drugs & Compounds for CYP2C9 Gene

Products:

  1. Drug

(534) Drugs for CYP2C9 Gene - From: DrugBank, PharmGKB, ClinicalTrials, ApexBio, HMDB, and Novoseek

Name Status Disease Links Group Role Mechanism of Action Clinical Trials
Acenocoumarol Approved, Investigational Pharma Enzyme, substrate 42
Celecoxib Approved, Investigational Pharma Inhibition, Inhibitor, Enzyme, substrate Selective cyclooxygenase-2 (COX-2) inhibitor 525
Flurbiprofen Approved, Investigational Pharma Channel blocker, Enzyme, substrate 70
Meloxicam Approved, Vet_approved Pharma Enzyme, substrate 101
Rifampicin Approved Pharma Agonist, Inhibition, Inhibitor, Enzyme, inducer Pregnane X receptor agonist; antibiotic 454

(99) Additional Compounds for CYP2C9 Gene - From: HMDB and Novoseek

Name Synonyms Role CAS Number PubChem IDs PubMed IDs
4'-Hydroxydiclofenac
  • (O-(2,6-dichloro-4-hydroxyanilino)Phenyl)acetic acid
  • 4'-Hydroxy diclofenac
  • 4'-OH DCF
  • (O-(2,6-dichloro-4-hydroxyanilino)Phenyl)acetate
  • {2-[(2,6-dichloro-4-hydroxyphenyl)amino]phenyl}acetic acid
 64118-84-9
nadph
  • 2'-(Dihydrogen phosphate) 5'-(trihydrogen pyrophosphate) adenosine 5'-ester with 1,4-dihydro-1-b-D-ribofuranosylnicotinamide
  • 2'-(Dihydrogen phosphate) 5'-(trihydrogen pyrophosphate) adenosine 5'-ester with 1,4-dihydro-1-beta-delta-ribofuranosylnicotinamide
  • Adenosine 5'-(trihydrogen diphosphate) 2'-(dihydrogen phosphate) p'-5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide
  • Adenosine 5'-(trihydrogen diphosphate) 2'-(dihydrogen phosphate) p'-5'-ester with 1,4-dihydro-1-beta-delta-ribofuranosyl-3-pyridinecarboxamide
  • b-NADPH
 53-57-6
Paraxanthine
  • 3,7-dihydro-1,7-Dimethyl-1H-purine-2,6-dione
  • P-Xanthine
  • 1,7-Dimethyl-xanthine
  • 1,7-Dimethylxanthine
 611-59-6
(-)-trans-Carveol
  • (-)-(4R,6S)-trans-Carveol
  • (1S,5R)-Carveol
  • Carveol
 1197-07-5
(R)-p-Mentha-1,8-dien-7-ol
  • (+)-Perillyl alcohol
  • (R)-(+)-Perillyl alcohol
  • (R)-4-(1-Methylethenyl)-1-cyclohexene-1-methanol
  • (R)-Perillyl alcohol
  • 4-(1-Methylethenyl)-(4R)-1-cyclohexene-1-methanol
 57717-97-2, 18457-55-1

(3) ApexBio Compounds for CYP2C9 Gene

Compound Action Cas Number
Amiodarone HCl Anti-arrhythmic drug 19774-82-4
Benzbromarone 3562-84-3
Gemfibrozil 25812-30-0
genes like me logo Genes that share compounds with CYP2C9: view

Drug Products

Transcripts for CYP2C9 Gene

Products:

  1. CRISPR
  2. miRNA
  3. Inhibitory RNA
  4. Clone

mRNA/cDNA for CYP2C9 Gene

1 REFSEQ mRNAs :
15 NCBI additional mRNA sequence :
5 Ensembl transcripts including schematic representations, and UCSC links to gene/alias where relevant :

CRISPR Products

Clone Products

Alternative Splicing Database (ASD) splice patterns (SP) for CYP2C9 Gene

ExUns: 1a · 1b · 1c ^ 2a · 2b ^ 3a · 3b ^ 4 ^ 5a · 5b ^ 6 ^ 7 ^ 8 ^ 9
SP1: - -
SP2: - - -
SP3: -
SP4:

Relevant External Links for CYP2C9 Gene

GeneLoc Exon Structure for
CYP2C9

Expression for CYP2C9 Gene

Products:

  1. Primer
  2. Gene Expression Assay

mRNA expression in normal human tissues from GTEx, Illumina, BioGPS, and SAGE for CYP2C9 Gene

mRNA expression in normal human tissues for CYP2C9 Gene
mRNA expression by GTEx for CYP2C9 GenemRNA expression by BioGPS for CYP2C9 Gene

mRNA expression in embryonic tissues and stem cells from LifeMap Discovery

mRNA differential expression in normal tissues according to GTEx for CYP2C9 Gene

This gene is overexpressed in Liver (x49.5).

Protein differential expression in normal tissues from HIPED for CYP2C9 Gene

This gene is overexpressed in Gallbladder (43.7) and Liver (24.5).

Integrated Proteomics: protein expression in normal tissues and cell lines from ProteomicsDB and MOPED for CYP2C9 Gene



Protein tissue co-expression partners for CYP2C9 Gene

- Elite partner

Transcriptomic regulation report from SPP (The Signaling Pathways Project) for CYP2C9

SOURCE GeneReport for Unigene cluster for CYP2C9 Gene:

Hs.282624

Evidence on tissue expression from TISSUES for CYP2C9 Gene

  • Heart(5)
  • Liver(5)
  • Blood(3)
  • Intestine(2.6)
  • Urine(2.2)

Phenotype-based relationships between genes and organs from Gene ORGANizer for CYP2C9 Gene

Germ Layers:
  • mesoderm
Systems:
  • cardiovascular
  • digestive
  • immune
  • lymphatic
Regions:
Thorax:
  • thymus
Abdomen:
  • liver
  • spleen
General:
  • blood
  • bone marrow
  • coagulation system
  • red blood cell
  • white blood cell
genes like me logo Genes that share expression patterns with CYP2C9: view

No data available for mRNA Expression by UniProt/SwissProt for CYP2C9 Gene

Orthologs for CYP2C9 Gene

This gene was present in the common ancestor of animals.

Orthologs for CYP2C9 Gene

Organism Taxonomy Gene Similarity Type Details
chimpanzee
(Pan troglodytes)
 Mammalia LOC100616515 30
  • 99.46 (n)
CYP2C9 31
  • 99 (a)
 OneToOne
cow
(Bos Taurus)
 Mammalia LOC505468 30
  • 83.79 (n)
-- 31
  • 79 (a)
 ManyToMany
CYP2C87 31
  • 78 (a)
 ManyToMany
CYP2C18 31
  • 78 (a)
 ManyToMany
-- 31
  • 77 (a)
 ManyToMany
rat
(Rattus norvegicus)
 Mammalia Cyp2c11 30
  • 80.75 (n)
mouse
(Mus musculus)
 Mammalia Cyp2c66 17 31 30
  • 80.54 (n)
Cyp2c29 31
  • 76 (a)
 ManyToMany
Cyp2c65 31
  • 76 (a)
 ManyToMany
Cyp2c39 31
  • 73 (a)
 ManyToMany
Cyp2c50 31
  • 73 (a)
 ManyToMany
Cyp2c37 31
  • 73 (a)
 ManyToMany
Cyp2c38 31
  • 72 (a)
 ManyToMany
Cyp2c54 31
  • 71 (a)
 ManyToMany
Cyp2c69 31
  • 67 (a)
 ManyToMany
Cyp2c67 31
  • 67 (a)
 ManyToMany
Cyp2c68 31
  • 66 (a)
 ManyToMany
Cyp2c40 31
  • 63 (a)
 ManyToMany
oppossum
(Monodelphis domestica)
 Mammalia -- 31
  • 68 (a)
 ManyToMany
-- 31
  • 67 (a)
 ManyToMany
-- 31
  • 67 (a)
 ManyToMany
-- 31
  • 65 (a)
 ManyToMany
-- 31
  • 64 (a)
 ManyToMany
fruit fly
(Drosophila melanogaster)
 Insecta Cyp18a1 32
  • 32 (a)
Cyp303a1 32
  • 26 (a)
worm
(Caenorhabditis elegans)
 Secernentea F42A9.5 32
  • 34 (a)
B0213.14 32
  • 33 (a)
F41B5.3 32
  • 33 (a)
B0213.12 32
  • 33 (a)
C12D5.7 32
  • 33 (a)
Y49C4A.9 32
  • 32 (a)
C49C8.4 32
  • 32 (a)
F44C8.1 32
  • 32 (a)
K09A11.3 32
  • 32 (a)
B0213.10 32
  • 32 (a)
F41B5.7 32
  • 32 (a)
T10H4.11 32
  • 32 (a)
B0304.3 32
  • 31 (a)
F41B5.4 32
  • 31 (a)
C45H4.2 32
  • 31 (a)
T09H2.1 32
  • 31 (a)
C34B7.3 32
  • 31 (a)
C41G6.1 32
  • 31 (a)
C45H4.17 32
  • 31 (a)
F41B5.2 32
  • 31 (a)
T10H4.10 32
  • 31 (a)
K09D9.2 32
  • 30 (a)
B0213.15 32
  • 30 (a)
F14H3.10 32
  • 30 (a)
K07C6.5 32
  • 29 (a)
R08F11.3 32
  • 29 (a)
K07C6.2 32
  • 29 (a)
C03G6.15 32
  • 29 (a)
K07C6.3 32
  • 29 (a)
B0213.16 32
  • 29 (a)
C49G7.8 32
  • 29 (a)
C25E10.2 32
  • 28 (a)
Y5H2B.6 32
  • 28 (a)
Species where no ortholog for CYP2C9 was found in the sources mined by GeneCards:
  • A. gosspyii yeast (Ashbya gossypii)
  • Actinobacteria (Mycobacterium tuberculosis)
  • African clawed frog (Xenopus laevis)
  • African malaria mosquito (Anopheles gambiae)
  • Alicante grape (Vitis vinifera)
  • alpha proteobacteria (Wolbachia pipientis)
  • amoeba (Dictyostelium discoideum)
  • Archea (Pyrococcus horikoshii)
  • baker's yeast (Saccharomyces cerevisiae)
  • barley (Hordeum vulgare)
  • beta proteobacteria (Neisseria meningitidis)
  • bread mold (Neurospora crassa)
  • chicken (Gallus gallus)
  • Chromalveolata (Phytophthora infestans)
  • common water flea (Daphnia pulex)
  • corn (Zea mays)
  • dog (Canis familiaris)
  • E. coli (Escherichia coli)
  • filamentous fungi (Aspergillus nidulans)
  • Firmicute bacteria (Streptococcus pneumoniae)
  • fission yeast (Schizosaccharomyces pombe)
  • green algae (Chlamydomonas reinhardtii)
  • honey bee (Apis mellifera)
  • K. lactis yeast (Kluyveromyces lactis)
  • lizard (Anolis carolinensis)
  • loblloly pine (Pinus taeda)
  • malaria parasite (Plasmodium falciparum)
  • medicago trunc (Medicago Truncatula)
  • moss (Physcomitrella patens)
  • orangutan (Pongo pygmaeus)
  • pig (Sus scrofa)
  • platypus (Ornithorhynchus anatinus)
  • rainbow trout (Oncorhynchus mykiss)
  • rice (Oryza sativa)
  • rice blast fungus (Magnaporthe grisea)
  • schistosome parasite (Schistosoma mansoni)
  • sea anemone (Nematostella vectensis)
  • sea squirt (Ciona intestinalis)
  • sea squirt (Ciona savignyi)
  • sea urchin (Strongylocentrotus purpuratus)
  • sorghum (Sorghum bicolor)
  • soybean (Glycine max)
  • stem rust fungus (Puccinia graminis)
  • sugarcane (Saccharum officinarum)
  • thale cress (Arabidopsis thaliana)
  • tomato (Lycopersicon esculentum)
  • toxoplasmosis (Toxoplasma gondii)
  • Trichoplax (Trichoplax adhaerens)
  • tropical clawed frog (Silurana tropicalis)
  • wheat (Triticum aestivum)
  • zebrafish (Danio rerio)

Evolution for CYP2C9 Gene

ENSEMBL:
Gene Tree for CYP2C9 (if available)
TreeFam:
Gene Tree for CYP2C9 (if available)
Aminode:
Evolutionary constrained regions (ECRs) for CYP2C9: view image

Paralogs for CYP2C9 Gene

Paralogs for CYP2C9 Gene

(38) SIMAP similar genes for CYP2C9 Gene using alignment to 12 proteins:

  • CP2C9_HUMAN
  • Q5EDC5_HUMAN
  • Q6IRV8_HUMAN
  • Q8WW80_HUMAN
  • Q9UEH3_HUMAN
  • Q9UQ59_HUMAN
  • S5R8G8_HUMAN
  • S5R8H1_HUMAN
  • S5RG22_HUMAN
  • S5RV20_HUMAN
  • S5RV29_HUMAN
  • S5RXA4_HUMAN
genes like me logo Genes that share paralogs with CYP2C9: view

Variants for CYP2C9 Gene

Products:

  1. SNP Genotyping and Copy Number Assay

Sequence variations, with clinical significance, from ClinVar and Humsavar, with links to dbSNP for CYP2C9 Gene

SNP ID Clinical significance and condition Chr 10 pos Variation AA Info Type
370010 Likely Benign, Drug Response: Lesinurad response; Flurbiprofen response; Piroxicam response; not provided 94,981,224(+) C/T
735596 Likely Benign: not provided 94,988,863(+) G/T SYNONYMOUS_VARIANT
755270 Likely Benign: not provided 94,941,953(+) T/C SYNONYMOUS_VARIANT
773002 Benign: not provided 94,949,217(+) A/G MISSENSE_VARIANT
776530 Benign: not provided 94,988,878(+) C/T SYNONYMOUS_VARIANT

Additional dbSNP identifiers (rs#s) for CYP2C9 Gene

Structural Variations from Database of Genomic Variants (DGV) for CYP2C9 Gene

Variant ID Type Subtype PubMed ID
esv2674280 CNV deletion 23128226
esv2739707 CNV deletion 23290073
esv2741937 CNV deletion 23290073
esv3624264 CNV gain 21293372
esv3624265 CNV gain 21293372
esv3891886 CNV loss 25118596
nsv1035409 CNV loss 25217958
nsv1047782 CNV gain 25217958
nsv551962 CNV loss 21841781
nsv551963 CNV loss 21841781
nsv7497 CNV insertion 18451855

Variation tolerance for CYP2C9 Gene

Residual Variation Intolerance Score: 87.8% of all genes are more intolerant (likely to be disease-causing)
Gene Damage Index Score: 6.04; 75.09% of all genes are more intolerant (likely to be disease-causing)

Additional Variant Information for CYP2C9 Gene

The Human Cytochrome P450 Allele Nomenclature Database
CYP2C9
Human Gene Mutation Database (HGMD)
CYP2C9
SNPedia medical, phenotypic, and genealogical associations of SNPs for
CYP2C9

No data available for Polymorphic Variants from UniProtKB/Swiss-Prot for CYP2C9 Gene

Disorders for CYP2C9 Gene

MalaCards: The human disease database

(38) MalaCards diseases for CYP2C9 Gene - From: OMIM, ClinVar, GTR, Orphanet, DISEASES, Novoseek, and GeneCards

- elite association - COSMIC cancer census association via MalaCards

Additional Disease Information for CYP2C9

Genetic Association Database
(GAD)
Human Genome Epidemiology Navigator
(HuGE)
ATLAS of Genetics and Cytogenetics in Oncology and Haematology
genes like me logo Genes that share disorders with CYP2C9: view

No data available for UniProtKB/Swiss-Prot and Genatlas for CYP2C9 Gene

Publications for CYP2C9 Gene

  1. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. (PMID: 18698879) Stehle S … Fuhr U (Clinical pharmacokinetics 2008) 3 23 26 41 54
  2. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. (PMID: 15606435) Zhang Y … Zhou H (British journal of clinical pharmacology 2005) 3 23 26 41 54
  3. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. (PMID: 20020283) Cadamuro J … Oberkofler H (European journal of clinical pharmacology 2010) 3 23 41 54
  4. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. (PMID: 19794411) Pautas E … Siguret V (Clinical pharmacology and therapeutics 2010) 3 23 41 54
  5. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. (PMID: 20089352) Tan L … Yu Y (Clinical neurology and neurosurgery 2010) 3 23 41 54

ExternalLinks

View latest publications for CYP2C9 gene in Mastermind

Products for CYP2C9 Gene

  • Biorbyt antibodies for CYP2C9

Sources for CYP2C9 Gene